This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Diabetes Insulin Guidance System granted a CE mark


8 October, 2012  
d-Nav is the world’s very first Diabetes Insulin Guidance System. DIGS automatically updates insulin dosage as needed, and provides its users with the updates immediately, rather than waiting for the next visit to a healthcare professional. Multiple studies have shown that insulin therapy is more effective when it is frequently adjusted based on an individual’s blood glucose patterns. 
 
Two major UK diabetes centres plan to start using d-Nav this autumn. Both will focus on insulin treated patients with poor glycemic control. 
 
The South Eastern Health and Social Care Trust’s Ulster Hospital in Northern Ireland will conduct a six-month d-Nav service evaluation, under the direction of Dr Roy Harper. 
 
The Heart of England Foundation Trust and the University of Birmingham are co-sponsoring a year-long observational study at the Heartlands Hospital in Birmingham, under the direction of Professor Martin Stevens. 
 
“Clinical evidence demonstrates that weekly insulin dosage adjustments can be safely made based solely on blood glucose data the patient generates. Unfortunately this knowledge doesn’t address the reality that our current healthcare delivery system lacks the time, attention or know-how to deliver that standard of care broadly,” says Professor Stevens. “Studies to date with DIGS have demonstrated the technology’s potential to bridge this gap between knowledge and more effective healthcare delivery to more people.” 
 
“d-Nav may provide the crucial ‘missing link’,” according to Dr Roy Harper, Evaluation Lead at the Ulster Hospital. “d-Nav updates each patient’s insulin dosage using their own individual insulin therapy regimen and their glucose patterns. Setting up our patients with d-Nav will put expert insulin dosage advice in the palms of their hands between their too infrequent clinic appointments. This could be the key to providing high quality diabetes healthcare to many more of those folks with type 2 diabetes using insulin therapy. d-Nav may transform the type of support we can give to our patients and help us move from traditional episodic interactions to a much more continuous level of patient support.”
 
“We look forward to observing the real-world use of d-Nav and our DIGS technology,” said Eran Bashan, Hygieia’s Chief Executive Officer. “The data Dr Harper, Professor Stevens and their teams collect will help Hygieia to assess the d-Nav value proposition.”